6 CSL Behring, King of Prussia, PA. RATIONALE: Hereditary angioedema (HAE) due to C1-esterase inhibitor (C1-INH) deficiency is known to have a significant negative impact on patients' health-related quality of life (HRQoL). We evaluated the impact of long-term prophylaxis with subcutaneous C1-INH ([C1-INH (SC)] Haegarda Ò , CSL Behring) on HRQoL in HAE patients treated in an openlabel extension (OLE) of the pivotal phase III COMPACT trial. METHODS: In the OLE, patients with > _4 HAE attacks within a consecutive 2-month period (N5126) self-administered C1-INH (SC) 40 or 60 IU/kg twice weekly for up to 52 or 140 weeks (US only). HRQoL was self-assessed by patients at various points during the OLE using several instruments, including the European Quality of Life-5 Dimensions (EQ-5D) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Work Productivity and Activity Impairment (WPAI) assessment. RESULTS: With C1-INH (SC) 60 IU/kg, significant improvements from baseline to the end-of-study visit were observed on the EQ-5D, HADS, and 3 of 4 WPAI domains. (-23.33 [-34.86, -11.81]), Work Productivity Loss (-26.68 [-39.92, -13.44]), and Activity Impairment (-16.14 [-26.36, -5.91] Barts Health NHS Trust, London, United Kingdom. RATIONALE: The plasma kallikrein inhibitor lanadelumab effectively prevented hereditary angioedema (HAE) attacks compared with placebo in the HELP Study (NCT02586805); 96.4% of lanadelumab-treated patients achieved > _50% attack rate reduction versus run-in period. We report exploratory findings for HELP Study ''nonresponder'' patients who had <50% reduction and continued lanadelumab treatment in the HELP OpenLabel Extension (OLE; NCT02741596). METHODS: In the HELP Study, patients > _12 years old with HAE type I/ II and > _1 attack/month during run-in were randomized to lanadelumab 150mg q4wks, 300mg q4wks, 300mg q2wks, or placebo. Patients continuing to the OLE received a single lanadelumab 300mg dose until first attack, then 300mg q2wks. Individual patient level data are described. RESULTS: Of 84 lanadelumab-treated patients in the HELP Study, 3 were identified as nonresponders; all had received lanadelumab 150mg q4wks, and continued in the OLE with 300mg q2wks. Monthly attack rates (attacks/4 weeks) for patient 1 during the HELP Study run-in (baseline) and treatment period, OLE treatment period, and OLE steady-state period were 1.93, 1.53 (21% reduction), 0.75, and 0.74, respectively. Attack rates for patient 2 were 1.00, 0.92 (8% reduction), 0.63, and 0.82, and for patient 3 were 1.00, 1.82 (82% increase), 0.92, and 0.19. Moderate/severe attack rates were reduced for all 3 patients when receiving 300mg q2wks. Patient 2 experienced 3 laryngeal attacks on 150mg q4wks but none on 300mg q2wks. CONCLUSIONS: Patients who did not respond to lanadelumab 150mg q4wks in the HELP Study experienced improvements with 300mg q2wks in the HELP OLE Study. 
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